FDOPA
Recurrent Childhood Brain Stem Glioma
Erik MittraSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Recurrent Childhood Brain Stem Glioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE Julie Krystal | Phase 2 | BB |
Irinotecan Julie Krystal | Phase 2 | BB |
Eloxatin National Cancer Institute (NCI) | Phase 2 | BB |
Mebendazole Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1/2 | B |
Veliparib National Cancer Institute (NCI) | Phase 1/2 | B |
View all 32 →
Same molecule, other indications
FDOPA is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →